A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

NCT04698642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Subcutaneous Fat

Interventions

DRUG: CBL-514

Sponsor

Caliway Biopharmaceuticals Co., Ltd.